Glen Coburn
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2016First federal award
$9.0MFederal grants as PI16 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
16 awards · $9.0M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jul 2, 2025 | NIH | SBIR Phase II Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infections | $1000K | VENATORX PHARMACEUTICALS INC |
| Jun 19, 2024 | NIH | SBIR Phase I Discovery of antiviral inhibitors for the treatment of orthopoxvirus infections | $300K | VENATORX PHARMACEUTICALS INC |
| May 17, 2024 | NIH | SBIR Phase II Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infections | $1.0M | VENATORX PHARMACEUTICALS INC |
| Jul 24, 2023 | NIH | SBIR Phase I Discovery of antiviral inhibitors for the treatment of orthopoxvirus infections | $300K | VENATORX PHARMACEUTICALS INC |
| Jun 6, 2023 | NIH | SBIR Phase II Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infections | $1.0M | VENATORX PHARMACEUTICALS INC |
| Mar 28, 2023 | NIH | SBIR Phase II Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection | $1.0M | VENATORX PHARMACEUTICALS INC |
| Apr 20, 2022 | NIH | SBIR Phase II Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection | $1.0M | VENATORX PHARMACEUTICALS INC |
| Oct 28, 2021 | NIH | SBIR Phase I Discovery of inhibitors that target HBx for the treatment of chronic HBV infection | $254K | VENATORX PHARMACEUTICALS INC |
| Jun 24, 2021 | NIH | SBIR Phase I Discovery of antiviral inhibitors of Ebola virus replication | $300K | VENATORX PHARMACEUTICALS INC |
| May 21, 2021 | NIH | SBIR Phase II Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection | $1.0M | VENATORX PHARMACEUTICALS INC |
| Dec 15, 2020 | NIH | SBIR Phase I Discovery of inhibitors that target HBx for the treatment of chronic HBV infection | $253K | VENATORX PHARMACEUTICALS INC |
| Jul 14, 2020 | NIH | SBIR Phase I Discovery of antiviral inhibitors of Ebola virus replication | $300K | VENATORX PHARMACEUTICALS INC |
| Feb 6, 2018 | NIH | SBIR Phase I Discovery of inhibitors of Zika virus | $300K | VENATORX PHARMACEUTICALS INC |
| Jun 28, 2017 | NIH | SBIR Phase I Discovery of inhibitors of BK polyomavirus | $343K | VENATORX PHARMACEUTICALS INC |
| Mar 6, 2017 | NIH | SBIR Phase I Discovery of inhibitors of Zika virus | $300K | VENATORX PHARMACEUTICALS INC |
| Jul 1, 2016 | NIH | SBIR Phase I Discovery of inhibitors of BK polyomavirus | $347K | VENATORX PHARMACEUTICALS INC |
Peer ranks
Federal funding#87
Awards as PI#37
Patents#273
Companies
- VENATORX PHARMACEUTICALS INCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.